
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial
Keywords: α-adrenergic receptors; β-adrenergic receptors; facial dermatoses; skin abnormalities; vascular skin diseases; vasoconstrictor agents; AE; adverse event; CEA; Clinician Erythema Assessment; CTA; Clinician Telangiectasia Assessment; SSA; Subject Self-Ass